“…Nonetheless, pharmacotherapies that either dampen NE transmission, such as the α1-adrenoceptor antagonist prazosin, the α2 agonist clonidine, and the non-selective β antagonist propranolol, or enhance NE transmission such as the α2 antagonist yohimbine, have shown some success in diminishing the exaggerated fear responding associated with PTSD (Belkin & Schwartz, 2015; Morris & Bouton, 2007; Powers, Smits, Otto, Sanders, & Emmelkamp, 2009; Raskind et al, 2003; Strawn & Geracioti, 2008; Tawa & Murphy, 2013; Taylor, Freeman, & Cates, 2008; Wangelin, Powers, Smits, & Tuerk, 2013). Yohimbine, as well as the non-selective β agonist isoproterenol, can enhance extinction learning (Cain, Blouin, & Barad, 2004; Do-Monte et al, 2010; Morris & Bouton, 2007; Powers et al, 2009), as well as memory consolidation or reconsolidation (Dębiec, Bush, & LeDoux, 2011; Gazarini, Stern, Carobrez, & Bertoglio, 2013). For these reasons, there has been a resurgence of interest in using noradrenergic drugs as adjuncts to cognitive-behavioral therapies for PTSD.…”